866-997-4948(US-Canada Toll Free)

Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat

Published By :

GBI Research

Published Date : Nov 2013

Category :

Therapeutic Area

No. of Pages : N/A


GBI Research has released its pharmaceutical research, \"Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 – Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat\", which provides insights into three cardiovascular therapeutic indications in the top eight markets of the US, the UK, Germany, France, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

Scope

  • Disease overview and treatment usage patterns
  • Market size and forecast for heart failure, Myocardial Infarction (MI) and Acute Coronary Syndrome (ACS)
  • Geographic coverage includes the top eight markets (the US, the UK, Germany, France, Italy, Spain, Japan and Canada) from 2012 to 2019
  • Major marketed products for the indications types covered
  • In-depth pipeline analysis for heart failure, MI and ACS
  • Key drivers and restraints that have had and are expected to have a significant impact upon the market
  • Key licensing and co-development agreements in the cardiovascular market

Reasons to Buy

The report will enhance your decision-making capability by allowing you to:

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
  • Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the cardiovascular market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 GBI Research Report Guidance

3 Therapeutic Landscape
3.1 Heart Failure
3.1.1 Symptoms
3.1.2 Etiology
3.1.3 Pathophysiology
3.1.4 Co-morbidities and Complications
3.1.5 Diagnosis
3.1.6 Classification
3.1.7 Prognosis and Disease Staging
3.1.8 Treatment Options
3.2 Myocardial Infarction
3.2.1 Symptoms
3.2.2 Etiology
3.2.3 Pathophysiology
3.2.4 Co-morbidities and Complications
3.2.5 Diagnosis
3.2.6 Classification
3.2.7 Treatment Options
3.3 Acute Coronary Syndrome
3.3.1 Symptoms
3.3.2 Etiology
3.3.3 Pathophysiology
3.3.4 Diagnosis
3.3.5 Treatment Options

4 Marketed Products
4.1 Heart Failure
4.2 Myocardial Infarction
4.3 Acute Coronary Syndrome
4.4 Key Marketed Products
4.4.1 Arixtra
4.4.2 Brilinta
4.4.3 Crestor
4.4.4 Diovan and Diovan HCT/Co-Diovan
4.4.5 Atacand
4.4.6 Lipitor
4.4.7 Clopidogrel bisulfate
4.4.8 Angiomax
4.4.9 Lovenox
4.4.10 Norvasc
4.4.11 Coreg
4.4.12 Ivabradine
4.4.13 Toprol-XL

5 Pipeline Analysis
5.1 Heart Failure Pipeline
5.1.1 Overall Pipeline
5.1.2 Pipeline Analysis by Molecule Type
5.1.3 Pipeline Analysis by Mechanism of Action
5.2 Myocardial Infarction Pipeline
5.2.1 Overall Pipeline
5.2.2 Pipeline Analysis by Molecule Type
5.2.3 Pipeline Analysis by Mechanism of Action
5.3 Acute Coronary Syndrome Pipeline
5.3.1 Overall Pipeline
5.3.2 Pipeline Analysis by Molecule Type
5.3.3 Pipeline Analysis by Mechanism of Action
5.4 Promising Drug Candidates in the Pipeline
5.4.1 LCZ-696
5.4.2 Darapladib (SB-480848)
5.4.3 Neucardin
5.4.4 Cangrelor
5.4.5 Serelaxin (Novartis AG)

6 Cardiovascular Diseases Global Market to 2019, Market Forecast
6.1 Global Market
6.1.1 Treatment Usage Patterns
6.1.2 Annual Cost of Treatment
6.1.3 Market Size
6.2 US
6.2.1 Treatment Usage Patterns
6.2.2 Annual Cost of Treatment
6.2.3 Market Size
6.3 France
6.3.1 Treatment Usage Patterns
6.3.2 Annual Cost of Treatment
6.3.3 Market Size
6.4 Spain
6.4.1 Treatment Usage Patterns
6.4.2 Annual Cost of Treatment
6.4.3 Market Size
6.5 Germany
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Treatment
6.5.3 Market Size
6.6 Italy
6.6.1 Treatment Usage Patterns
6.6.2 Annual Cost of Treatment
6.6.3 Market Size
6.7 UK
6.7.1 Treatment Usage Patterns
6.7.2 Annual Cost of Treatment
6.7.3 Market Size
6.8 Japan
6.8.1 Treatment Usage Patterns
6.8.2 Annual Cost of Therapy
6.8.3 Market Size
6.9 Canada
6.9.1 Treatment Usage Patterns
6.9.2 Annual Cost of Treatment
6.9.3 Market Size
6.10 Drivers and Barriers for the Global Cardiovascular Diseases Market
6.10.1 Drivers
6.10.2 Barriers

7 Deals and Strategic Consolidations
7.1 Deals Analysis
7.2 Major Co-development Deals
7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics
7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics
7.2.3 Cytokinetics Signs Strategic Agreement with Amgen
7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc.
7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc.
7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited
7.3 Major Licensing Deals
7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine
7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc.
7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc.
7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb
7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck & Co., Inc. for Cardiovascular Therapeutic Candidates
7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc.
7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck & Co, Inc.
7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics

8 Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Sources
8.4 All Pipeline Drugs by Phase
8.4.1 Preclinical
8.4.2 Pre-registration
8.4.3 Phase I
8.4.4 Phase II
8.4.5 Phase III
8.4.6 Discontinued
8.4.7 Filing rejected/Withdrawn
8.5 Market Forecasts to 2019
8.5.1 Global
8.5.2 US
8.5.3 UK
8.5.4 France
8.5.5 Spain
8.5.6 Germany
8.5.7 Italy
8.5.8 Japan
8.5.9 Canada
8.6 Research Methodology
8.6.1 Coverage
8.6.2 Secondary Research
8.6.3 Primary Research
8.6.4 Therapeutic Landscape
8.6.5 Geographical Landscape
8.6.6 Pipeline Analysis
8.7 Expert Panel Validation
8.8 Contact Us
8.9 Disclaimer

List of Table


Table 1: Cardiovascular Diseases Market Global, General Symptoms of Congestive Heart Failure by Stage, 2013
Table 2: Cardiovascular Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 3: Cardiovascular Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013
Table 4: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 5: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 6: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 7: Cardiovascular Market, Global, Pharmaceutical Pipeline (Discontinued), 2013
Table 8: Cardiovascular Market, Global, Pharmaceutical Pipeline (Filing rejected Withdrawn), 2013
Table 9: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Global, Market Forecast, 2012-2019
Table 10: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Global, Market Forecast, 2012-2019
Table 11: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Global, Market Forecast, 2012-2019
Table 12: Cardiovascular Diseases in Global Market to 2019, Heart Failure, US, Market Forecast, 2012-2019
Table 13: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, US, Market Forecast, 2012-2019
Table 14: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, US, Market Forecast, 2012-2019
Table 15: Cardiovascular Diseases in Global Market to 2019, Heart Failure, UK, Market Forecast, 2012-2019
Table 16: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, UK, Market Forecast, 2012-2019
Table 17: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, UK, Market Forecast, 2012-2019
Table 18: Cardiovascular Diseases in Global Market to 2019, Heart Failure, France, Market Forecast, 2012-2019
Table 19: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, France, Market Forecast, 2012-2019
Table 20: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, France, Market Forecast, 2012-2019
Table 21: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Spain, Market Forecast, 2012-2019
Table 22: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Spain, Market Forecast, 2012-2019
Table 23: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Spain, Market Forecast, 2012-2019
Table 24: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Germany, Market Forecast, 2012-2019
Table 25: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Germany, Market Forecast, 2012-2019
Table 26: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Germany, Market Forecast, 2012-2019
Table 27: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Italy, Market Forecast, 2012-2019
Table 28: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Italy, Market Forecast, 2012-2019
Table 29: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Italy, Market Forecast, 2012-2019
Table 30: Cardiovascular Diseases Market to 2019, Heart Failure, Japan, Market Forecast, 2012–2019
Table 31: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Japan, Market Forecast, 2012–2019
Table 32: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Japan, Market Forecast, 2012–2019
Table 33: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Canada, Market Forecast, 2012-2019
Table 34: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Canada, Market Forecast, 2012-2019
Table 35: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Canada, Market Forecast, 2012-2019

List of Chart


Figure 1: Cardiovascular Diseases Market, Global, Heart Failure Treatment Algorithm, 2013
Figure 2: Cardiovascular Diseases Market, Global, Subtypes of Myocardial Infarction by Clinical Scenario, 2013
Figure 3: Cardiovascular Diseases Market, Global, Acute Coronary Syndrome Treatment Algorithm, 2013
Figure 4: Cardiovascular Diseases Market , Arixtra, Global, Annual Sales ($m), 2009–2012
Figure 5: Cardiovascular Diseases Market, Brilinta, Global, Annual Sales ($m), 2011–2012
Figure 6: Cardiovascular Diseases Market, Crestor, Global, Annual Sales ($m), 2009–2012
Figure 7: Cardiovascular Diseases Market to 2019, Lovenox, Global, Annual Sales ($m), 2009–2012
Figure 8: Cardiovascular Diseases Market, Coreg, Global, Annual Sales ($m), 2006–2012
Figure 9: Cardiovascular Diseases Market to 2019, Toprol-XL, Global, Annual Sales ($m), 2007–2012
Figure 10: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline, 2012
Figure 11: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Molecule Type, 2012
Figure 12: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Mechanism of Action, 2012
Figure 13: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline, 2012
Figure 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Molecule Type, 2012
Figure 15: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Mechanism of Action, 2012
Figure 16: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline, 2012
Figure 17: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Molecule Type, 2012
Figure 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Mechanism of Action, 2012
Figure 19: Cardiovascular Diseases Global Market to 2019, Market Size ($m), 2012–2019
Figure 20: Cardiovascular Diseases Global Market to 2019, US, Market Size ($m), 2012–2019
Figure 21: Cardiovascular Diseases Global Market to 2019, France, Market Size ($m), 2012–2019
Figure 22: Cardiovascular Diseases in Global Market to 2019, Spain, Market Size ($m), 2012–2019
Figure 23: Cardiovascular Diseases in Global Market to 2019, Germany, Market Size ($m), 2012–2019
Figure 24: Cardiovascular Diseases in Global Market to 2019, Italy, Market Size ($m), 2012–2019
Figure 25: Cardiovascular Diseases in Global Market to 2019, UK, Market Size ($m), 2012–2019
Figure 26: Cardiovascular Diseases in Global Market to 2019, Japan, Market Size ($m), 2012–2019
Figure 27: Cardiovascular Diseases in Global Market to 2019, Canada, Market Size ($m), 2012–2019
Figure 28: Cardiovascular Diseases Market to 2019, Global, Deals, 2007–2013
Figure 29: Cardiovascular Market, Global, Co-development Deals, 2007–2013
Figure 30: Cardiovascular Diseases Market to 2019, Global, Licensing Deals, 2007–2013
Figure 31: GBI Research Market Forecasting Model

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *